Clinical Trial Update: Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016) [Phase 3]

View source ↗

Summary

Phase 3 trial MK-7655A-016 comparing Imipenem/Cilastatin/Relebactam to Piperacillin/Tazobactam in hospital-acquired and ventilator-associated pneumonia complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hospital-acquired Pneumonia
• Ventilator-associated Pneumonia

Drugs mentioned

• Imipenem/Cilastatin/Relebactam (imipenem/cilastatin/relebactam)
• Piperacillin/tazobactam (Piperacillin/tazobactam)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia | Phase 3 | Status: COMPLETED | Results posted: 2023-06-28